Purpose To evaluate the advantages and disadvantages of pre-approval requirements for safety data to detect cardiovascular (CV) risk contained in the December 2008 U.S. Food and Drug Administration (FDA) guidance for developing type 2 diabetes drugs compared with the February 2008 FDA draft guidance from the perspective of diabetes population health. Methods We applied the incremental net health benefit (INHB) framework to quantify the benefits and risks of investigational diabetes drugs using a common survival metric (life-years [LYs]). We constructed a decision analytic model for clinical program development consistent with the requirements of each guidance and simulated diabetes drugs, some of which had elevated CV risk. Assuming constant research budgets, we estimate the impact of increased trial size on drugs investigated. We aggregate treatment benefit and CV risks for each approved drug over a 35-year horizon under each guidance. Results The quantitative analysis suggests that the December 2008 guidance adversely impacts diabetes population health. INHB was À1.80 million LYs, attributable to delayed access to diabetes therapies (À0.18 million LYs) and fewer drugs (À1.64 million LYs), but partially offset by reduced CV risk exposure (0.02 million LYs). Results were robust in sensitivity analyses. Conclusion The health outcomes impact of all potential benefits and risks should be evaluated in a common survival measure, including health gain from avoided adverse events, lost health benefits from delayed or forgone efficacious products, and impact of alternative policy approaches. Quantitative analysis of the December 2008 FDA guidance for diabetes therapies indicates that negative impact on patient health will result.
INTRODUCTION
Over the last decade, drug safety has become an increasingly important regulatory issue. Drug withdrawals have raised concerns about the adequacy of benefit-risk assessment, 1 and numerous reports have considered or advocated changes in risk management (WHO/UNESCO joint report, 2 PDUFA III, 3 IOM report, 4 and U.S. Food and Drug Administration (FDA) guidance documents [5] [6] [7] [8] ).
Although the need to consider benefits as well as risks has been a major theme in FDA guidance, concerns about excess acute myocardial infarctions and sudden deaths associated with rofecoxib 9 and potentially elevated cardiovascular (CV) risk for patients treated with rosiglitazone 10 have increased focus on risk 11 and contributed to re-evaluation of CV risk associated with the sulfonylurea class, which has been available for over 50 years. 12 Partially in response to these concerns, the FDA published draft guidance for developing type 2 diabetes drugs in February 2008. 13 In this draft, the FDA increased pre-approval safety data requirements but did not suggest a specific CV clinical endpoint in the absence of an adverse signal (Table 1) . In December 2008, the FDA published final guidance 14 that recommended endpoints pre-approval and post-approval to rule out specific levels of CV risk without explicit consideration of drug benefits. Implementation of the February 2008 draft guidance would have increased clinical trial size compared with the status quo. The endpoints recommended in the final December 2008 guidance, however, require substantially larger and longer clinical studies, with recent launches having CV endpoint studies to address this requirement totaling approximately 25 000-50 000 patient life-years (LYs) and at least one compound (dutogliptin) apparently stopping development in part due to the increased expense to meet this requirement. 15, 16 Few studies, however, have evaluated the cost-effectiveness of pharmaceutical regulation; one recent example compared a regulation to no regulation scenario for QT/QTc studies for drugs under development. [15] [16] [17] The new requirements bring advantages through early detection of risk but also impose costs through larger and longer clinical trials that can slow access for patients and reduce the incentives to develop new drugs. The reduction in speed of access to drugs with favorable risk-benefit profiles provides a first-order cost to patients, whereas reduced investment in diabetes treatments would lead to an additional secondorder cost to patients. Against these costs must be weighed the benefits from reduced exposure to drugs with less favorable risk-benefit profiles that might be detected earlier.
Joint evaluation of these factors requires a complex model of the ecosystem and many assumptions about critical variables. Published quantitative analyses of celecoxib and rofecoxib (COX-2 inhibitors) used such models to compare benefits and risks of these treatments with other NSAIDs among rheumatoid arthritis (RA) populations. 18, 19 Using discrete-event simulation modeling of CV and gastrointestinal risks, these studies found that COX-2 inhibitors increased RA population health (as measured by quality-adjusted LYs) over a 1-year horizon. When evaluating the consequences of additional safety testing on adverse events based on the rofecoxib withdrawal, expanded pre-approval studies could have reduced adverse events, but an evaluation of both benefits and risks was beyond the study scope. 20 Expanding preapproval studies can always increase the likelihood of detecting putative adverse effects of a drug, but a more comprehensive assessment of the benefits and risks specific to a particular situation is needed to determine what trial size provides the appropriate balance. 21 In addition, whether it is more efficient to conduct these studies pre-approval or post-approval needs to be considered, recognizing that the trade-off may vary across drugs. In this paper, we discuss the merits of decision modeling as a tool to explore and clarify the broader potential impacts of a decision, using the FDA guidance on testing for CV risk of diabetes therapies as a case study. Previous research examining the impact of this guidance found large increases in review time (2×), trial size (2.5×), and trial patient-years (4×) after the December 2008 guidance. 23 In other research, it has been suggested that including additional types of CV risk in the safety endpoint might mitigate this impact by allowing more efficient detection of CV-related risk. 24 Our evaluation is unique in that it provides a more complete quantitative analysis of the long-term impacts of this policy decision on diabetes population health. Although the assumptions and approaches used herein are subject to debate, the need to model the impacts of major regulatory changes is clear. Decision modeling can provide insight into whether a change in policy is likely to achieve its key objectives without offsetting consequences.
METHODS
We used a decision analysis model to estimate health benefits and risks associated with development under the two policy frameworks-the December 2008 guidance and the February 2008 draft guidance-to calculate incremental net health benefit (INHB), measured in LYs, for the diabetes population over a 35-year horizon (20 years during which the drug is commonly used, 3 years of use by a particular patient, and 12 years of subsequent impact on that patient [with declining benefit over time]). Specifically, we applied a validated and structured, quantitative health outcomes approach 25 to estimate INHB by simulating investigational drugs with constant treatment benefit but variable CV risk. The key drivers are the time to detection of CV risks and the foregone benefits associated with treatments that might be delayed, not reach market, or not be investigated.
Decision analysis model structure
The decision analysis model was based on decision trees that represent the least costly of several approaches to meet the recommendations of each guidance (see Figure 1 ). We developed a simulation model in Microsoft Excel based on the decision trees, following a set of diabetes drugs through development and approval and calculating their net impact on the diabetes population. Individual drugs were assumed to have a constant effect on survival associated with HbA1c control but could have either no CV risk or elevated CV risk drawn from a specified distribution; drugs with elevated CV risk had higher Phase III attrition, particularly under the December 2008 guidance, and were withdrawn from the market when the risk was identified. The constant base-case survival impact of improved HbA1c control derives from a published estimate for 0.5% improvement, 26 and this assumption is consistent with decreasing HbA1c improvement averaging 0.5% over 3 years use by a patient. The HbA1c effect on survival (LYs) is varied in sensitivity analyses. In the base case, overall research and development budgets for diabetes drugs were held constant, leading to a reduction in the number of investigated drugs. This assumption is based on pharmaceutical research budgets having been a relatively constant proportion of sales over the past 20 years and relatively flat in absolute terms in the last 2 years, 27 leading to tradeoffs in research portfolios. This assumption may be conservative, as companies would be expected to shift investment away from diabetes if the cost/benefit ratio for that area becomes more negative relative to other potential investments.
The supporting information provides details of the decision analysis model and policy frameworks.
Model inputs
Where possible, we used historical or published data on type 2 diabetes drugs, drug development, and costs (Table 2 and supporting information). The probability a drug had any elevated CV risk (CV death, myocardial infarction, and stroke), 4.4%, was based on the combined percentage of investigational compounds entering Phase III that failed (1987) (1988) (1989) (1990) (1991) (1992) , the percentage of terminations at least 4 years from initial filing of the new drug due to safety problems (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) , and the percentage of marketed drugs that were withdrawn or restricted due to safety signals (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . 1, 28, 29 In the absence of information on the magnitude of CV relative risk ratio (RRR) in investigational diabetes drugs that have elevated risk, we used a beta distribution (α = 0.80; β = 2.46) parameterized to advantage the safety benefit provided by the December 2008 guidance by setting the mean RRR equal to the lower risk threshold (1.3) specified in that guidance and the 97.5th percentile equal to the upper risk threshold (1.8) specified in that guidance; drugs with moderate risk-as opposed to those likely to be detected under either scenario-would accordingly be well represented in our modeling exercise.
We based our inputs for the design, duration, and cost of the clinical trial programs on requirements in the guidance frameworks and estimates of new drug development costs (in 2010 dollars). 13, 14, [29] [30] [31] [32] We used 0.5 years as a conservative estimate of the additional time required to run the larger Phase III trials. The probability of detecting elevated CV risk cv risk evaluation for diabetes 271 was calculated based on the estimated power of the clinical trial programs to detect elevated incidence of CV events for the simulated CV RRR. The base case assumes that each simulated drug reduces a long-term blood glucose measure (HbA1c) compared with standard of care for appropriately targeted patients by 0.5 percentage points (an assumed value so that effectiveness exceeds non-inferiority of 0.3 to 0.4 13 ), is effective at controlling glucose levels for 3 years per patient, and has no residual effects beyond 10 years. Risk and benefit are assumed proportional to exposure time, so duration of maintained control is unlikely to affect risk-benefit comparison. We assume these parameter values to illustrate the impact of the policy change on effective agents. Although not all agents would confer the assumed level and duration of control, we explore variation in effectiveness assumptions through sensitivity analysis.
Sensitivity analysis
We conducted sensitivity analyses to assess the impact of parameter uncertainty. For CV risk assumptions, we varied the mean risk, risk variance, and risk distribution to consider risk scenarios favorable to increased pre-approval scrutiny. We adjusted treatment efficacy and survival assumptions, we considered alternative assumptions for delay to market, and we relaxed the fixed pharmaceutical budget assumption. Parameter values were varied by plus and minus 25% in the sensitivity analyses, except for share of drugs (+50%) and delay to market (À0.25 years/+1.0 years) to reflect greater uncertainty in future drug development. To control for sampling variation, all sensitivity analyses used the same 10 000 random elevated CV risks drawn from the CV relative risk distribution.
RESULTS

Base-case analyses
The Table 3 ). In addition, the December 2008 guidance also leads to a reduction in the number of drugs investigated (see Methods), which further reduces the number of CV events.
The increased safety requirements have a modest survival impact. Model estimates indicate a 0.4% increase in LYs for individual treated patients due to the increased safety requirements. This perspective ignores survival benefits from reductions in time on market and number of drugs approved. The impact is small primarily because relatively few diabetes agents have elevated CV risks, and even under the February 2008 draft guidance, those with elevated CV risks are withdrawn from the market.
The INHB of the December 2008 guidance is negative when the delayed time to market and number of drugs investigated are considered (see Table 3 ). Thus, the foregone survival (LY) benefits (the policy costs) from delayed approval and reduced clinical research for investigational diabetes agents exceed the survival benefits associated with reductions in CV risk. The average net benefit per investigated drug decreases 3.3%, factoring in the improved safety requirements and the delayed approval. Thus, the foregone survival benefit of HbA1c control from only a 0.5 year delay in launch per investigated drug outweighs the realized survival benefit of reduced CV risk associated with the safety requirements. For the entire diabetes population, factoring in reductions in the capacity to investigate new drugs, the model estimates a 37.6% reduction in net benefits. From the diabetes patient population perspective, the December 2008 guidance reduces patient health when estimated using survival. Table 4 presents a disaggregation of populationlevel INHB. The negative estimated INHB for the type 2 diabetes population (À1.80 million LYs) is attributable to delayed access to efficacious diabetes therapy (À0.18 million LYs) and a reduction in the number of drugs approved (À1.64 million LYs), partially offset by reduced exposure to drugs with elevated CV risk (0.02 million LYs).
Sensitivity analysis
One-way analysis. Results were robust to all one-way sensitivity analyses (see Table 5 for INHB and number of CV events per investigated drug and total). All sensitivity analyses resulted in (i) reductions in INHB per investigated drug and in total, and (ii) reductions in CV events per investigated drug and in total. The lowest predicted reduction in LYs per investigated drug was À3716 (for a quarter year delay to market); the lowest predicted reduction in LYs resulted in the extended useful life of investigation drugs (À1.13 million LYs), and no one-way sensitivity analyses came close to predicting an increase in INHB in the policy comparison.
Reducing the clinical benefit of HbA1c improvement by 25% (to 0.038 LYs over 10 years) reduced the impact of the December guidance to À1.34 million LYs. Accordingly, the benefit of HbA1c improvement would need to be considerably lower than 0.038 LYs over 10 years for the CV event risk reduction to outweigh the foregone survival benefits of control.
Model results were also robust to alternative CV risk assumptions. Increasing the share of investigational drugs with elevated CV risk by 50% (to 6.63%) decreased total INHB only slightly to À1.76 million LYs, and decreasing number of CV events by 7186 instead of 7064. If the average elevated risk was 1.43 (vs. 1.30), total INHB decreased to À1.78 million. The number of CV events avoided actually decreases in this scenario to 6300 given earlier detection in the February 2008 standard for drugs of this risk profile. Table 5 presents additional absolute changes in INHB and number of CV events for one-way sensitivity analyses exploring parameter uncertainty. In all cases, the December 2008 guidance reduced INHB of diabetes patients even though it reduced CV events.
Scenario analysis. Expanded use of post-marketing surveillance could provide reductions in CV events without accompanying reductions in health benefit. Tripling participation in required surveillance programs under the February 2008 draft guidance achieved up to a 41.6% reduction in CV events provided by the safety requirements in the December 2008 guidance (see Table 6 ) without adverse health impacts from delay to market or reduced incentives to innovate.
Model results are robust to relaxing the fixed research budget assumption. If, as an extreme scenario, one assumed budgets increased to avoid any impact on cv risk evaluation for diabetes 273 the number of drugs developed for diabetes, the December 2008 guidance results in a decrease in INHB of 160 000 LYs (the combined impact of improved safety and negative impact of delayed access; see Table 4 ).
DISCUSSION
Given safety concerns associated with rosiglitazone, 10 the FDA increased the evidentiary requirements for approving new diabetes therapies in 2008. Longer and larger trials with more high-risk patients are required. These stricter requirements should lead to earlier detection of drugs with elevated CV risk, reducing the likelihood of marketing approval and widespread adoption. These requirements also raise development cost for new diabetes therapies, lowering the return to manufacturers and likely leading to fewer new molecular entities reaching the market. The question is whether the evidence standard provides an appropriate balance of benefits and costs for diabetes patients. We evaluated these trade-offs by constructing a decision analysis model for representative new diabetes therapies using health benefits and risks measured in terms of expected LYs and compared the December 2008 guidance for developing type 2 diabetes agents with the February 2008 draft guidance (a guidance that itself required additional evidence compared with the status quo). Using the illustrative case of investigational agents with minimum clinically meaningful effectiveness, some of which had elevated CV risk, we found that (i) the December 2008 guidance effectively reduced CV events but with modest survival benefit because few drugs that have elevated CV risk reach Phase III; (ii) foregone treatment benefits from delayed approval exceed survival benefits from improved safety (INHB is negative); and (iii) INHB is substantially worsened when considering budget and/or incentive implications of the additional clinical development costs.
Our findings suggest that focusing solely on reducing CV risk may not benefit diabetes patients overall. This study shows that losses from discouraging or delaying effective drugs without elevated CV risk may outweigh gains from the increased likelihood of early identification of drugs with elevated CV risk, an issue that was raised in a recent FDA Advisory Committee meeting. 33 Other options, including increased use of postapproval controlled trials or observational data collection, or other means to balance risk and benefit might prove preferable. The recent FDA Advisory Committee vote to recommend approval of the longlasting insulin degludec, but require a CV outcomes trial post-approval, is consistent with this alternative approach. 34 The analyses presented here highlight the need for more rigor in assessing both pre-approval benefit-risk trade-offs and post-marketing data.
Our model is limited by data availability, requiring assumptions for model inputs from multiple sources. We assume constant treatment effectiveness equal to the minimum clinically meaningful result and explore the importance of this parameter in sensitivity analyses. Future clinical assumptions are inherent in the model: we assume no improvement in pre-diabetes medication, no improvement in treatments for CV events, and no impact of changing population characteristics. Similarly, we apply averages from historical clinical studies to the potentially changing population without explicit modeling of patient heterogeneity. Although we perform extensive sensitivity analyses for these parameters, model results remain dependent on these assumptions.
The findings from our analyses complement those of previous studies, 20, 22 which report "substantial negative economic effects" from increased pre-approval requirements, particularly those increasing the length of pre-approval clinical trials. 22 Sizable increases in post-approval safety evaluation were much less detrimental. 20 These studies noted, however, that preapproval and post-approval data collections were not perfect substitutes and that there was a key benefitrisk determination to be made, particularly in the case of potentially fatal events. In analysis of the effects of requiring larger pre-approval safety databases, the studies note that an increase from 2000 to 4000 patients was cost-effective in a rofecoxib-like example but an increase to 8000 was not. These studies did not, however, consider relative risks as low as those covered by the December 2008 guidance, assumed little effective post-marketing surveillance, and did not consider the impact of increased testing on either the number or timing of drug approvals, in contrast to the analyses presented here.
Model findings may not represent the full impact of policy changes on the health of patients in the USA because of effects on other parties. Our model assumed fixed total research budgets for diabetes therapies, but pharmaceutical and biotechnology companies may substitute away from investments in diabetes to other areas because of the altered return on investment, potentially leading to more therapies reaching market for other diseases. Alternatively, they might continue to invest in diabetes but focus their efforts on drugs that are likely to have greater CV benefit (e.g., ancillary benefit for hypertension), making it easier to achieve the risk thresholds and providing additional valued properties. This paper introduces a structured, quantitative health outcomes model to assess the benefit-risk trade-offs of a change in healthcare policy. Although views may differ regarding the assumptions used for the example studied herein, sensitivity analyses and conservative assumptions indicate a degree of robustness for our findings. We believe that it is critical to model all key potential benefits and risks of a policy decision, including direct benefits or losses from the change and indirect effects that may occur because of the change. Only in this context can a potential choice be compared with alternatives in order to understand the likely outcomes of a major policy change.
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